June 21, 2018
Immunocompetent Murine Models for Immunotherapy Assessment
Immunocompetent models are necessary for the preclinical assessment of novel immunotherapies, but multiple murine model platforms are available for the evaluation of cross reactive and surrogate agents. Here we look at syngeneics, GEMM, and murine tumor homograft models and how to choose the best model for your immuno-oncology study.
LEARN MORE
June 19, 2018
DGAT2 Inhibition Doesn’t Affect Plasma Triglycerides, VLDL ApoB
In a new study published in Cell Metabolism, McClaren et al utilize a variety of translational models, including both ...
LEARN MORE
June 15, 2018
Mouse Models of Multiple Sclerosis
Multiple sclerosis is a chronic disease affecting the central nervous system, which has multiple stages and currently ...
LEARN MORE
June 12, 2018
Leveraging PDX Models for In Vitro and Ex Vivo Assays
Patient-derived xenografts (PDX) are the most predictive and translational xenograft models available for preclinical ...
LEARN MORE
June 7, 2018
Is an Approved NASH Therapy on the Way?
Non-alcoholic steatohepatitis (NASH) is an unmet medical need with no approved therapies and debilitating consequences ...
LEARN MORE
June 5, 2018
PDX and Personalized Medicine
We discussed patient-derived xenografts (PDX) previously, from how to establish the models to when to add them to ...
LEARN MORE
May 31, 2018
Predictive Immuno-Oncology Studies with Humanized PDX
Patient-derived xenograft (PDX) models are typically immunodeficient and inappropriate for most immuno-oncology (I/O) drug discovery. Humanized PDX models, however, have functional human immune systems for therapeutic modulation. This opens up new applications for these highly predictive models in the immuno-oncology research space.
LEARN MORE
May 29, 2018
Webinar FAQ: PDX Models in Drug Discovery Assays
Patient-derived xenografts (PDX) are the most predictive and translational preclinical xenograft models available for ...
LEARN MORE
May 24, 2018
Webinar FAQ: Humanized PDX Models in Immuno-Oncology
Patient-derived xenografts (PDX) support highly translational preclinical oncology research, but were historically ...
LEARN MORE
May 22, 2018
Immuno-Oncology and the Microbiome at AACR 2018
CrownBio presented thirteen posters at AACR 2018, sharing our latest internal research into patient derived xenografts, ...
LEARN MORE
May 17, 2018
Genetically Engineered or Syngeneic Mouse Models?
Mouse models are a mainstay of preclinical cancer research, and immunocompetent model use is rising with continued interest in immuno-oncology. Two of the most widely used immunotherapy research models are syngeneic and genetically engineered mouse models (GEMM), but which best support your strategic research goals?
LEARN MORE
May 15, 2018
Murine Homograft Tumor Models at AACR 2018
We presented a wide range of immuno-oncology model data at AACR 2018, with three of our thirteen posters covering our ...
LEARN MORE
May 10, 2018
In Vitro and Ex Vivo Assay Platforms at AACR 2018
We presented a wide range of oncology modelling capabilities at AACR 2018, spanning the breadth of preclinical ...
LEARN MORE
May 8, 2018
Latest Data on PDX Models at AACR 2018
We presented the latest data on our PDX models at this year’s AACR Annual Meeting in Chicago, with new studies on DLBCL ...
LEARN MORE
May 3, 2018
Humanized Mouse Model Posters at AACR 2018
CrownBio presented thirteen posters at AACR 2018, showcasing a wide range of our oncology and immuno-oncology ...
LEARN MORE
